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Introduction
Human African trypanosomiasis, also known as sleeping sickness, 
is a vector-borne parasitic disease and a serious health threat to a large 
number of people living in sub-Saharan Africa, where health systems 
are challenged at best [1-3]. Trypanosoma brucei gambiense (T. b. 
gambiense) and Trypanosoma brucei rhodesiense (T. b. rhodesiense) 
are the etiological parasites that cause sleeping sickness in humans. 
These parasites live and grow extracellularly in the blood and tissue 
fluids of humans or cattle and are transmitted among hosts by tsetse 
flies (Glossina spp.). Without effective treatment, the disease can lead 
to coma and ultimately death. If the patients do not receive treatment 
in a timely manner, the neurological damage caused by these parasites 
is irreversible even after treatment [3,4]. Current drugs used to treat 
human trypanosomiasis include Suramin, Pentamidine, Melarsoprol and 
Eflornithine [5], however, these drugs do not effectively treat the disease, 
maintaining an urgent need for new, more effective and less expensive 
drugs for the treatment of human African trypanosomiasis [4-6].
Tubulin is a very attractive target in the field of anti-cancer drug 
discovery, and several successful tubulin binders are used clinically 
as first-line chemotherapeutic agents [7]. Tubulin also plays an 
essential role during trypanosome cell division. The fast, population-
doubling rate of trypanosomes makes them highly dependent on 
tubulin polymerization/depolymerization [8]. More importantly, 
tubulin is critical for trypanosome locomotion, which is essential for 
trypanosomes survival. Tubulin inhibitors not only block T. brucei 
cell division but also affect the locomotive functions of flagellum and 
lead to cell death [9]. Some microtubule-disrupting herbicides, such 
as phosphoric thioamide herbicide Amiprophos-Methyl (APM) and 
dinitroaniline herbicides, exhibit activity against protozoan parasites 
by targeting tubulin [10-14]. Research works have optimized these 
compounds, generating more potent and selective tubulin inhibitors for 
T. brucei [10]. Webovertz’s group successfully developed several drug 
candidates that show promising anti-parasite activity and selectivity in 
vitro. However, these compounds did not show substantial potency in 
vivo due to their poor stability [15]. 
Recently, we have developed a class of tubulin inhibitors as 
anti-cancer agents [16,17]. These compounds share the same core 
scaffold and bind to a colchicine-binding domain on tubulin [16]. 
We performed T. brucei cell-growth inhibition assays with our 
compounds, some of which exhibited very specific inhibitory effects on 
T. brucei growth resulting in selectivity indices (IC50 inhibiting human 
cancer cell growth/IC50 inhibiting T. brucei cell growth) of 5 or more. 
Among these compounds, BMCL26 has been identified as a potential 
drug candidate. BMCL26 exhibited activity against T. brucei cell 
proliferation with an IC50 of 1.62 µM but inhibited mammalian cell 
growth with an IC50 of 55.35 µM [18]. The selective index of BMCL26 is 
approximately 34, and its IC50 (for inhibiting T. brucei proliferation) is 
in the low micromolar range, which is obtainable in blood. The present 
investigation addresses the critical need of developing a method to 
accurately quantify BMCL26 concentrations in blood. Thus, in this 
paper, we report the development and validation of a robust and highly 
sensitive LC-MS/MS method for quantitating BMCL26 in rat plasma 
with an LLOQ of 0.5 ng/mL and a linear calibration range of up to 100 
ng/mL.
Experimental
Chemicals and reagents
BMCL26 and JCC76 (internal standard) were synthesized and 
purified according to previously published procedures [18,19]. 
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Abstract
BMCL26 is a potential drug derived from nimesulide, which has exhibited the substantial anti-parasitic activity in 
various cell lines. To conduct various pharmacological and toxicological properties of this drug, we developed and 
validated a rapid LC-MS/MS method for its quantification in accordance with the FDA guidelines. Protein precipitation 
with 0.1% formic acid in acetonitrile was used to extract the analytes along with the internal standard (JCC76) from 
rat plasma. It was found that the calibration curve of the method had an excellent linearity (r2 ≥ 0.9993) for the analyte 
concentration ranging from 0.5 to 100 ng/mL with acceptable inter- and intra-assay, precision, accuracy and stability. 
The matrix effect and extraction recovery were in the range of 101.30-110.10% and 90.16- 105.00%, respectively. 
This LC-MS/MS method is simple and rapid and can be used in the future pharmaceutical studies of BMCL26.
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Methanol (HPLC grade) and acetonitrile were from Pharmco-Apper 
(Philadelphia, Pennsylvania, USA). Formic acid and ammonium 
acetate (analytical grade) were purchased from Sigma Aldrich 
Chemical Company (Allentown, Pennsylvania, USA). Deionized water 
was obtained using a Barnstead Nano pure water purification system 
with a Nanopure Diamond Pack Organic free DI cartridge from 
Thermo Scientific (Waltham, Massachusetts, USA). Six individual lots 
of rat plasma (Sprague-Dawley rat plasmas K2) were obtained from 
Innovative Research (Novi, Michigan, USA) (Figure 1).
Calibration standards and quality-control samples
Preparation of stock and working solutions: A set of BMCL26 
working solutions containing 10, 20, 50, 150, 400, 1000 and 2000 ng/
mL were prepared by serial dilution using methanol and 1 mg/mL 
stock solution. The 150 ng/mL working solution of JCC76 (IS) was 
diluted from a stock solution of 1 mg/mL in methanol. Stock solutions 
and working solutions were stored at -20°C and 4°C.
Calibration and preparation of quality-control (QC) plasma 
samples
Calibration plasma samples were prepared by spiking 10 µl of 
corresponding BMCL26 working solutions in 200 µl of rat plasma 
(mixture of 6 lots) with drug concentrations of 0.5, 1.0, 2.5, 5, 12.5, 25, 
50, and 100 ng/mL. QC samples at three concentrations, 1.25 (low), 
10 (mid) and 80 (high) ng/mL, were prepared by adding 10 µL of the 
appropriate BMCL26 working solution and 200 µL of drug-free plasma. 
Calibration and QC samples were frozen at -20°C overnight and then 
treated using the following sample preparation procedure before LC-
MS/MS analysis.
Sample extraction
QC samples and blanks were removed from the -20°C freezer and 
thawed to room temperature. Ten µl of JCC76 working solution were 
spiked into each 200 μL aliquot of plasma calibrators/QCs/blanks, 
excepting the double blank, into which 10 µL of acetonitrile was added. 
The solutions were then vortexed immediately for 30 sec, after which 
each sample was deproteinized by adding 800 µl of 0.1% formic acid 
in acetonitrile, sonicating for 15 minutes, and centrifuging at 13,000 
× g for 15 minutes. The supernatants were then transferred into auto 
sampler vials for LC-MS/MS analysis. 
LC-MS/MS analysis
LC-MS/MS analysis was performed using a 5500 Q-TRAP triple 
quadrupole, tandem mass spectrometer (AB Sciex, Toronto, Canada) 
coupled with an Electrospray Ionizer (ESI) operated in negative ion 
mode (Framingham, Massachusetts, USA) and interfaced with High 
Performance Liquid Chromatography (HPLC, Shimadzu, Columbia, 
Maryland, USA) system that uses auto-sampling and online vacuum 
degassing. All data acquisition and processing were conducted using 
Analyst software, version 1.5.2 (AB Sciex).
Analytical separation of BMCL26 was achieved using a Luna C8 
(2) HPLC column (50 × 2.0 mm, 5 micron) with a C8 security-guard 
cartridge from Phenomenex (Torrance, California, USA). Mobile 
phase A contained 50 µM ammonium acetate in 2% Methanol, 
and mobile phase B contained 50 µM ammonium acetate in 90% 
Methanol. Sample aliquots of 5 µl were injected onto the column and 
eluted via the following gradient flow: 0-0.6 min, 70% B, 1.6 min, 90% 
B, 7.5 min, and stop (Table 1). The column was equilibrated for 0.5 
min before each run. Negative electrospray ionization (ESI) mode 
was selected, and the MRM (multiple reaction monitoring) function 
was used for quantification, with the transitions set at m/z 573.3 
→ 493.2 for BMCL26 and m/z 443.2 → 79.1 for JCC76 (IS) (Figure 
2), respectively. The following ion-source-dependent parameters 
were used: nebulization gas (30), heating gas (30), curtain gas (35), 
ion spray voltage (-4330 ev) and temperature (500°C). Compound-
dependent parameters were manually optimized as follows: 
declustering potential, -40; entrance potential, -10; collision energy 
and cell exit potential for both analyte and internal standard, -30, 
-100, -13, and -9.
              (A)                                                                 (B)                              
             
   JCC76          BMCL26 
Figure 1: The chemical structures of JCC76 (A), internal standard BMCL26 (B).
Figure 1: The chemical structures of JCC76 (A), internal standard BMCL26 (B).
             Minutes Event Parameters
0-0.6 B% 70 (isocratic)
0.6-1.6 B% 70-90 (liner)
0-3.5 Total flow 0.25 ml/min
3.5-3.7 Total flow 0.25-0.6 ml/min
1.6-5.5 B% 90 (isocratic)
5.5-5.6 B% 90-70 (liner)
3.5-5.9 Total flow 0.6 ml/min
5.9-6.0 Total flow 0.25-0.6 ml/min
5.6-7.5 B% 70 (liner)
Table 1: HPLC gradient program.
Figure 2: Precursor/product ion spectra and proposed fragmentation pathways 
for internal standard JCC76 (A) and analyte BMCL26 (B).
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Analytical method validation 
The LC-MS/MS assay was fully validated according to the Food and 
Drug Administration (FDA) Bioanalytical Method Guidelines [20] and 
other references [21-23]. The entire assay was validated for linearity, 
accuracy, precision, selectivity, extraction recovery, matrix effect and 
stability.
Linearity and calibration 
Eight concentrations of BMCL26 (0.5, 1.0, 2.5, 5, 12.5, 25, 50, and 
100 ng/mL) were selected for the plasma calibration curve (n=2 for 
each of the eight calibrators, average for each calibrator plotted). A 
weighed linear regression, using 1/x as the weighing factor, was used to 
calculate the slope and correlation coefficient of the calibration curve.
Accuracy and precision
To determine the intra- and inter-day accuracy and precision of the 
assay, we tested five replicates of BMCL26 at the LQC, MQC, and HQC 
using 1.25, 10 and 80 ng/mL. Intra-assay and inter-assay precisions 
were defined as Relative Standard Deviations (RSD) between replicate 
measurements. Accuracies were calculated using the following formula: 
accuracy (%)=(experimental concentration - spiked concentration)/
(spiked concentration) × 100. The criteria for data acceptability 
included accuracy and precisions within ± 15% of the nominal value 
and the RSD.
Extraction recovery and matrix effects
The extraction recoveries and matrix effects of BMCL26 for three 
concentrations of QC samples (low, 1.25 ng/mL; medium, 10 ng/
mL; and high, 80 ng/mL) were determined by comparing peak areas 
of analyte-spiked plasma aliquots before extraction to peak areas of 
analyte-spiked solutions extracted from blank plasma and comparing 
the response of solutions spiked with analyte after extraction to the 
response of analyte dissolved in the mobile phase.
Stability studies
The stabilities of BMCL26 in rat plasma samples were determined 
using two distinct QC standards (1.25 and 80 ng/mL), which were 
tested after 8 hours at room temperature and after two months at -20°C; 
freeze-thaw stabilities were determined using three freeze-thaw cycles 
over a three day period. Short-term stabilities were also determined 
for post-preparation QC standards stored at room temperature for 
10 hours. The QC results obtained after storage were compared with 
spiked concentration values by determining the percentage ratios of 
experimental values divided by spiked values.
The stabilities of stock and working solutions for both analyte 
and internal standard were also evaluated. Stock solutions of analyte 
and IS were stored at -20°C for 9 months. From both stored and fresh 
stock solutions, two QC standards (1.25 and 80 ng/mL) were prepared 
for the analyte, to which 7.5 ng/mL IS (JCC76) was added, and the 
experimentally determined concentrations of BMCL26 and JCC76 
were compared (n=3 for each).
Results and Discussion
Optimization of mass spectrometric conditions for 
quantitation
The negative ionization mode was selected for both BMCL26 and 
JCC76 (IS) detection in this study because the analyte produced a much 
stronger signal for negative ionization compared to positive ionization. 
It was found that analyte and IS solutions prepared in methanol-water 
(9:1, v/v) yielded stronger signals compared to solutions prepared 
in acetonitrile-water (9:1, v/v). Adding ammonium acetate to the 
methanol-water solution substantially increased BMCL26 signals. 
Therefore, a gradient flow of methanol-water-ammonium acetate was 
chosen for the HPLC mobile phase. Figure 2 showed the parent ion 
spectra for both BMCL26 and IS. The highest fragment-ion signals 
were obtained by fine-tuning the collision energy, spray voltage, and 
ion source temperature. Based on our ionization and fragmentation 
optimization results, we chose MRM transitions of m/z 573.2 → 493.2 
for BMCL26 and 443.2 → 79.1 for IS for quantification, as these product 
ions yielded strong and stable signals. 
Optimization of HPLC conditions
The gradient flow of the mobile phase, which was used with different 
flow rates, was as follows: A: 50 µM ammonium acetate in 2% methanol 
and mobile phase; B: 50 µM ammonium acetate in 90% methanol (Table 
1). Because the C-18 column had a carry-over problem with BMCL26, 
a C-8 column was used instead. The C-8 column effectively resolved the 
carryover problem and also yielded a better peak shape. Thus, BMCL26 
and IS were separated using a C-8 column with a flow rate of 0.25 mL/
min for 3.5 min, after which the flow rate was increased to 0.6 mL/
min for column clean up and re-equilibration. Retention times were 
observed at 2.51 min for BMCL26 and 3.14 min for IS (Figure 3). The 
total run time was 8 min.
Linearity, sensitivity, selectivity and LLOQ
Using the concentrations of BMCL26 in the working solutions, 
plasma calibration curves were constructed over a concentration range 
Figure 3: (A) MRM chromatograms of blank rat plasma in both IS and Analyte 
windows (B) IS JCC76 (10 ng/ml, 3.12 min) and BMCL26 at LLOQ level (0.5 
ng/ml, 2.48 min).
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of 0.5-100 ng/mL. Linearity results showed a quadratic fit for BMCL26 
using an eight-point calibration curve (0.5, 1, 2.5, 5, 12.5, 25, 50, and 100 
ng/mL) with JCC76 (7.5 ng/mL) as the internal standard in the plasma 
samples. Excellent linearity was obtained with a correlation coefficient 
(r2) of 0.9993. The linear regression equation was y=0.073x-0.0085. This 
method exhibited high selectivity and displayed no interfering peaks in 
six different blank plasma samples from different sources. Using the 
calibration curve, the LLOQ of the method was determined to be 0.5 
ng/mL. The accuracy and precision were determined for each lot of 
plasma at the LLOQ. The data were summarized in Table 2.
Accuracy and precision
Intra- and inter-assay accuracies (%RE) and precisions (%CV) 
were evaluated by analyzing five replicates of low, medium, and high 
QC standards. As summarized in Table 3, the assay’s intra- and inter-
day relative errors were 0.62 and 11.36%, respectively, and the assay’s 
intra- and inter-day precisions were 0.84-3.47%, respectively. These 
values were within acceptable limits according to FDA guidelines.
Extraction recovery and matrix effects 
It was found that protein precipitation was a good way to 
extract BMCL26 from plasma. Initially, we used 80% acetonitrile to 
precipitate plasma proteins, but a strong matrix effect was observed. 
Consequently, we utilized pure acetonitrile to precipitate proteins 
with 0.1% formic acid (for deproteinization). The latter precipitation 
conditions eliminated the matrix effect and achieved symmetrical 
chromatographic peak shapes. The absolute and relative extraction 
recoveries were in the range of 90.16-105.00%. The results were 
summarized in Table 4. As shown in Table 5, the absolute and relative 
matrix effects of BMCL26 from six different rat plasma samples at three 
QC concentrations (low (1.25 ng/mL), medium (10 ng/mL), and high 
(80 ng/mL) ranged from 101.30-110.10%.
Stability
The stability of BMCL26 was determined by comparing the mean 
peak area ratios of BMCL26 to IS in low (1.25 ng/mL) and high (80 ng/
Nominal Concentration (ng/mL) Determined Concentration (ng/mL) Accuracy (%RE) Precision (%CV)
0.5 0.47 ± 0.03 -7.46 5.59
1 0.99 ± 0.02 -0.22 2.09
2.5 2.54 ± 0.05 1.40 2.01
5 5.14 ± 0.27 2.80 5.24
12.5 12.75 ± 0.31 2.00 2.41
25 25.27 ± 0.73 1.08 2.90
50 51.03 ± 0.97 2.06 1.90
100 98.26 ± 0.99 -1.74 1.01
Table 2: Accuracy and precision of BMCL26 calibration standards in rat plasma (n=5, pooled plasma samples).
Intra-assay Inter-assay
Normal  (ng/ml) Determined (ng/ml) Accuracy (%RE) SD Precision (%CV) Determined (ng/ml) Accuracy (%RE) SD Precision (%CV)
1.25 1.20 11.36 0.02 1.72 1.36 9.12 0.04 3.38
10 10.20 2.00 0.16 1.64 10.20 2.00 0.35 3.43
80 80.70 0.87 0.68 0.84 80.50 0.62 2.80 3.47
Table 3: Inter and intra-assay accuracy and precision of BMCL26 in rat plasma.
Concentration of QC samples(ng/ml) Absolute Relative
1.25
Mean extraction recovery %CV Mean extraction recovery %CV
104.00 ± 4.89 4.70 98.10 ± 9.73 9.92
10 105.00 ± 4.99 4.75 95.96 ± 3.61 3.76
80   96.30 ± 3.00 3.12 90.16 ± 2.87 3.18
Table 4: Absolute and relative Extraction recovery of BMCL26 in rat plasma.
Storage conditions Concentration (ng/ml) Recovery %
Bench top (8 hr) 1.25 103.46
At room temp 80.00 103.20
Freeze thaw (3 cycles)
1.25 98.13
80.00 105.20
Post extraction 1.25 101.86
(10 hr) at room temp 80.00 107.54
Table 6: Stability of BMCL26 in plasma samples.
Concentration of QC samples(ng/ml) Absolute Relative
1.25
Mean matrix effect %CV Mean matrix effect %CV
105.00  ±  1.07 1.02 108.00  ±  5.15 4.77
10 107.00  ±  6.06 5.66 110.10  ±  8.99 8.17
80 105.00  ±  3.86 3.68 101.30  ±  4.78 4.72
Table 5: Absolute and relative matrix effect of BMCL26 in rat plasma.
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mL) QC samples to those of freshly prepared QC solutions (containing 
the same concentrations), expressed in terms of recovery. As shown in 
Table 6, the receives of LQC and HQC samples were 103.46-103.20%, 
98.13-105.20%, and 101.86-107.54% for bench top conditions, after 
3 freeze-thaw cycles and post extraction at room temperature for 10 
hours, respectively. The stabilities of working solutions of BMCL26 
and internal standard (JCC76), stored at 4°C for at least 6 months, 
were determined to be 99.60-105.00% and 115.60% for the two 
QC standards tested (1.25 and 80 ng/mL), to which 7.5 ng/mL IS 
was added (using the stored stock solution). These stability results 
showed no significant deviations in BMCL26 quantification under the 
experimental conditions used.
Conclusion
This innovative method offers several advantages for assaying 
BMCL26 in rat plasma including simplicity, cost effectiveness, 
accuracy and precision were below 11% and 3%, with high sensitivity 
and selectivity. To our knowledge, this is the first time this method was 
used. This assay employed a simple protein precipitation procedure for 
plasma sample preparation. The LLOQ was as low as 0.5 ng/mL. The 
results from the validation study illustrated that this method can be 
used to determine the pharmacological and toxicological profiles of 
BMCL26 in rats in the future.
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